Barclays PLC Protagonist Therapeutics, Inc Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Barclays PLC holds 126,995 shares of PTGX stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126,995
Previous 126,995 -0.0%
Holding current value
$5.17 Million
Previous $5.71 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$33.72 - $47.33 $2.96 Million - $4.15 Million
87,755 Added 223.64%
126,995 $5.71 Million
Q2 2024

Aug 14, 2024
SELL
$24.66 - $34.8 $556,798 - $785,749
-22,579 Reduced 36.52%
39,240 $1.36 Million
Q1 2024

May 15, 2024
SELL
$21.79 - $32.15 $1.9 Million - $2.8 Million
-87,155 Reduced 58.5%
61,819 $1.79 Million
Q4 2023

Feb 15, 2024
SELL
$14.05 - $23.44 $391,475 - $653,108
-27,863 Reduced 15.76%
148,974 $3.42 Million
Q3 2023

Nov 07, 2023
SELL
$16.68 - $23.66 $276,921 - $392,803
-16,602 Reduced 8.58%
176,837 $2.95 Million
Q2 2023

Aug 03, 2023
SELL
$18.02 - $29.36 $7.03 Million - $11.5 Million
-390,298 Reduced 66.86%
193,439 $5.34 Million
Q1 2023

May 04, 2023
BUY
$10.78 - $25.38 $3.55 Million - $8.35 Million
328,850 Added 129.02%
583,737 $13.4 Million
Q4 2022

Feb 13, 2023
BUY
$7.36 - $11.17 $286,252 - $434,434
38,893 Added 18.01%
254,887 $2.78 Million
Q3 2022

Nov 03, 2022
BUY
$7.86 - $11.71 $1.51 Million - $2.25 Million
192,463 Added 817.91%
215,994 $1.82 Million
Q2 2022

Aug 12, 2022
SELL
$7.06 - $25.52 $146,643 - $530,075
-20,771 Reduced 46.89%
23,531 $186,000
Q1 2022

May 16, 2022
SELL
$23.34 - $36.08 $1.78 Million - $2.75 Million
-76,295 Reduced 63.26%
44,302 $1.05 Million
Q4 2021

Feb 14, 2022
BUY
$17.63 - $37.1 $1.47 Million - $3.1 Million
83,600 Added 225.96%
120,597 $4.12 Million
Q3 2021

Nov 09, 2021
BUY
$12.95 - $49.69 $383,216 - $1.47 Million
29,592 Added 399.62%
36,997 $656,000
Q2 2021

Aug 13, 2021
SELL
$25.57 - $44.88 $778,887 - $1.37 Million
-30,461 Reduced 80.44%
7,405 $333,000
Q1 2021

May 13, 2021
BUY
$19.02 - $31.15 $518,447 - $849,086
27,258 Added 256.96%
37,866 $981,000
Q4 2020

Feb 11, 2021
SELL
$18.49 - $25.13 $72,462 - $98,484
-3,919 Reduced 26.98%
10,608 $214,000
Q3 2020

Nov 12, 2020
BUY
$15.19 - $22.4 $29,407 - $43,366
1,936 Added 15.38%
14,527 $284,000
Q2 2020

Aug 12, 2020
BUY
$6.19 - $18.84 $41,460 - $126,190
6,698 Added 113.66%
12,591 $222,000
Q1 2020

May 13, 2020
SELL
$5.4 - $9.22 $67,829 - $115,812
-12,561 Reduced 68.07%
5,893 $42,000
Q4 2019

Feb 10, 2020
BUY
$4.69 - $13.45 $18,553 - $53,208
3,956 Added 27.29%
18,454 $130,000
Q3 2019

Nov 14, 2019
SELL
$9.41 - $16.56 $98,588 - $173,499
-10,477 Reduced 41.95%
14,498 $174,000
Q2 2019

Aug 14, 2019
SELL
$8.98 - $12.96 $355,554 - $513,138
-39,594 Reduced 61.32%
24,975 $302,000
Q1 2019

May 15, 2019
SELL
$6.5 - $13.77 $26,214 - $55,534
-4,033 Reduced 5.88%
64,569 $812,000
Q4 2018

Feb 14, 2019
BUY
$6.3 - $10.44 $432,192 - $716,204
68,602 New
68,602 $462,000
Q3 2018

Nov 14, 2018
SELL
$6.82 - $11.26 $167,274 - $276,174
-24,527 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$5.99 - $9.1 $75,773 - $115,115
12,650 Added 106.51%
24,527 $164,000
Q1 2018

May 15, 2018
BUY
$8.46 - $23.08 $30,972 - $84,495
3,661 Added 44.56%
11,877 $102,000
Q4 2017

Feb 14, 2018
BUY
$14.47 - $20.8 $115,760 - $166,400
8,000 Added 3703.7%
8,216 $171,000
Q3 2017

Nov 14, 2017
BUY
$10.61 - $17.98 $2,291 - $3,883
216
216 $4,000

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email